Robert Stratta to Liver Transplantation
This is a "connection" page, showing publications Robert Stratta has written about Liver Transplantation.
Connection Strength
0.857
-
Orlando G, Wood KJ, Soker S, Stratta RJ. How regenerative medicine may contribute to the achievement of an immunosuppression-free state. Transplantation. 2011 Oct 27; 92(8):e36-8; author reply e39.
Score: 0.388
-
Stratta R, Shaefer M, Markin R, Bradshaw K, Donovan J, Wood R, Langnas A, Reed E, Woods G, Zetterman R, et al. Ganciclovir therapy for viral disease in liver transplant recipients. Transplant Proc. 1991 Jun; 23(3):1968.
Score: 0.094
-
Stratta R, Shaefer M, Bradshaw K, Wood R, Langnas A, Zetterman R, Donovan J, Sorrell M, Markin R, Shaw BW. Experience with OKT3 after orthotopic liver transplantation. Transplant Proc. 1991 Jun; 23(3):1970.
Score: 0.094
-
Grewal HP, Shokouh-Amiri MH, Vera S, Stratta R, Bagous W, Gaber AO. Surgical technique for right lobe adult living donor liver transplantation without venovenous bypass or portocaval shunting and with duct-to-duct biliary reconstruction. Ann Surg. 2001 Apr; 233(4):502-8.
Score: 0.047
-
Grewal H, Amiri H, Vera S, Stratta R, Whitington G, Lazar L, Black D, Powell S, Ammons J, Gaber AO. In-situ split-liver transplantation. Tenn Med. 1999 Nov; 92(11):411-4.
Score: 0.042
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):635-7.
Score: 0.026
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):641-3.
Score: 0.026
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):679-88.
Score: 0.026
-
Orlando G, Wood KJ, De Coppi P, Baptista PM, Binder KW, Bitar KN, Breuer C, Burnett L, Christ G, Farney A, Figliuzzi M, Holmes JH, Koch K, Macchiarini P, Mirmalek Sani SH, Opara E, Remuzzi A, Rogers J, Saul JM, Seliktar D, Shapira-Schweitzer K, Smith T, Solomon D, Van Dyke M, Yoo JJ, Zhang Y, Atala A, Stratta RJ, Soker S. Regenerative medicine as applied to general surgery. Ann Surg. 2012 May; 255(5):867-80.
Score: 0.025
-
Orlando G, DomÃnguez-Bendala J, Shupe T, Bergman C, Bitar KN, Booth C, Carbone M, Koch KL, Lerut JP, Neuberger JM, Petersen B, Ricordi C, Atala A, Stratta RJ, Soker S. Cell and organ bioengineering technology as applied to gastrointestinal diseases. Gut. 2013 May; 62(5):774-86.
Score: 0.025
-
Shaw BW, Markin R, Stratta R, Langnas A, Donovan J, Sorrell M. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. Transplant Proc. 1991 Dec; 23(6):2994-5.
Score: 0.024
-
Orlando G, Baptista P, Birchall M, De Coppi P, Farney A, Guimaraes-Souza NK, Opara E, Rogers J, Seliktar D, Shapira-Schweitzer K, Stratta RJ, Atala A, Wood KJ, Soker S. Regenerative medicine as applied to solid organ transplantation: current status and future challenges. Transpl Int. 2011 Mar; 24(3):223-32.
Score: 0.023
-
Winsett RP, Arheart K, Stratta RJ, Alloway R, Wicks MN, Gaber AO, Hathaway DK. Evaluation of an immunosuppressant side effect instrument. Prog Transplant. 2004 Sep; 14(3):210-6, 240.
Score: 0.015